These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 30536208)

  • 1. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
    Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
    Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.
    Bracci S; Osti MF; Agolli L; Bertaccini L; De Sanctis V; Valeriani M
    Radiat Oncol; 2016 Jun; 11():78. PubMed ID: 27276878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
    Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
    Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.
    Hervás A; Gómez-Caamaño A; Casaña M; Gómez-Iturriaga A; Pastor J; Jove J; Mengual JL; Gónzalez-San Segundo C; Muñoz J
    Clin Transl Oncol; 2018 Feb; 20(2):193-200. PubMed ID: 28667448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
    Tendulkar RD; Reddy CA; Stephans KL; Ciezki JP; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1397-404. PubMed ID: 21665379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy : TROD 09-001 multi-institutional study.
    Ozyigit G; Onal C; Igdem S; Alicikus ZA; Iribas A; Akin M; Yalman D; Cetin I; Aksu MG; Atalar B; Dincbas F; Hurmuz P; Guler OC; Aydin B; Sert F; Yildirim C; Gorken IB; Agaoglu FY; Korcum AF; Yuce D; Ozkok S; Darendeliler E; Akyol F
    Strahlenther Onkol; 2019 Oct; 195(10):882-893. PubMed ID: 31143994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients.
    Van Hemelryk A; De Meerleer G; Ost P; Poelaert F; De Gersem W; Decaestecker K; De Visschere P; Fonteyne V
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):323-332. PubMed ID: 27598803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate Cancer.
    Rice SR; Olexa G; Hussain A; Mannuel H; Naslund MJ; Amin P; Kwok Y
    Am J Clin Oncol; 2019 Mar; 42(3):285-291. PubMed ID: 30676332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
    Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.
    King MT; Chen MH; Moran BJ; Braccioforte MH; Buzurovic I; Muralidhar V; Yang DD; Mouw KW; Devlin PM; D'Amico AV; Nguyen PL; Orio PF
    Urol Oncol; 2018 Apr; 36(4):157.e15-157.e20. PubMed ID: 29276060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.
    Zumsteg ZS; Zelefsky MJ; Woo KM; Spratt DE; Kollmeier MA; McBride S; Pei X; Sandler HM; Zhang Z
    BJU Int; 2017 Nov; 120(5B):E87-E95. PubMed ID: 28464446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
    Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
    Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort.
    Marotte D; Gal J; Schiappa R; Gautier M; Boulahssass R; Chand-Fouche ME; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2022 Jul; 35():104-109. PubMed ID: 35692263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer.
    Boladeras A; Santorsa L; Gutierrez C; Martinez E; Pera J; Pino F; Suarez JF; Ferrer F; Díaz A; Polo A; Guedea F
    Radiother Oncol; 2014 Aug; 112(2):227-32. PubMed ID: 25174299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
    Matzkin H; Chen J; Agai R; Ziv-Baran T; Mabjeesh NJ
    PLoS One; 2019; 14(4):e0215582. PubMed ID: 31002732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.